SKYE — Skye Bioscience Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug
Brief: Skye Bioscience Says Kaitlyn Arsenault To Step Down As CFO Effective Feb 20
Brief: Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab
U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
U.S. STOCKS ON THE MOVE-Qualcomm, Costco, Topgolf Callaway Brands
U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive
Skye Bioscience rises as it partners with Halozyme on obesity drug
Skye's obesity drug misses mid-stage trial main goal, shares tank (updated)
Skye plunges as weight-loss drug misses main goal in mid-stage study
U.S. STOCKS ON THE MOVE-Gilead, energy companies, Abercrombie & Fitch
U.S. STOCKS ON THE MOVE-Figure Technology, Spruce Biosciences, Verizon
Skye falls as weight-loss drug misses main goal in mid-stage study
Skye Bioscience's obesity drug fails to meet main goal of mid-stage study (updated)
Skye Bioscience's obesity drug fails to meet main goal of mid-stage study
Brief: Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab
H.C. Wainwright initiates coverage of Skye Bioscience with 'buy' rating
Brief: Skye’S Cb1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss And Differentiated Mechanisms From Monlunabant, And Continues To Show Enhanced Combination With Tirzepatide With Durable Post-Treatment Weight Maintenance In Dio Model
Skye Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary